Second Alzheimer's drug can slow disease by a few months
Another experimental Alzheimer's drug can modestly slow patients' inevitable worsening — by about four to seven months, researchers reported Monday.
Stay updated with breaking news from Mark Mintun. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Another experimental Alzheimer's drug can modestly slow patients' inevitable worsening — by about four to seven months, researchers reported Monday.
Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.
Donanemab was found to slow "clinical decline" by up to 35%, allowing people with the disease to continue performing day-to-day tasks such as shopping, housekeeping, managing their finances and taking medication.
Another experimental Alzheimer's drug can modestly slow patients' inevitable worsening — by about four to seven months, researchers reported Monday.
Another experimental Alzheimer's drug can modestly slow patients' inevitable worsening — by about four to seven months, researchers reported Monday.